

## Subject: Hepatitis C Drug Will Be Discontinued

Janssen Therapeutics, a company of Johnson and Johnson, is withdrawing Olysio® (simeprevir) from the U.S. market.<sup>1</sup> Olysio is a protease inhibitor approved in 2013 for use in combination with other antiviral drugs to treat hepatitis C. In subsequent years, alternative hepatitis C drugs have been widely adopted due to less complicated dosing. Given this change in the market, Janssen Therapeutics has now decided Olysio is obsolete. The official date for discontinuation will be May 25, 2018; however, supplies are expected to be exhausted before this date.

### The Impact

The discontinuation should not have an effect on injured workers receiving Olysio. If there is the need to find an alternative, patients should work with their doctor to ensure they have the needed supply to finish a complete 12-week course of therapy and discuss alternative options as needed.

For more information, please contact your Account Manager or Account Pharmacist.

<sup>1</sup> <https://www.genengnews.com/gen-news-highlights/jjs-janssen-halts-development-of-hepatitis-c-combo-jnj-4178-citing-market-change/81254910>